CEM-101 is a novel fluoroketolide with lower MICs than those of telithromycin and macrolides. Our aim was to assess the cellular accumulation and intracellular activity of CEM-101 using models developed for analyzing the pharmacokinetics and pharmacological properties of antibiotics against phagocytized bacteria. We used THP-1 macrophages and Staphylococcus aureus (ATCC 25923 [methicillin (meticillin) sensitive]), Listeria monocytogenes (strain EGD), and Legionella pneumophila (ATCC 33153). CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively). This intracellular accumulation was suppressed by incubation at a pH of <6 and by monensin (proton ionophore) and was unaffected by verapamil (P-glycoprotein inhibitor; twofold accumulation increase for azithromycin) or gemfibrozil. While keeping with the general properties of the macrolide antibiotics in terms of maximal efficacy (E max ; approximately 1-log 10 -CFU decrease compared to the postphagocytosis inoculum after a 24-h incubation), CEM-101 showed significantly greater potency against phagocytized S. aureus than telithromycin, clarithromycin, and azithromycin (for which the 50% effective concentration [EC 50 ] and static concentrations were about 3-, 6-, and 15-fold lower, respectively). CEM-101 was also about 50-fold and 100-fold more potent than azithromycin against phagocytized L. monocytogenes and L. pneumophila, respectively. These differences in EC 50 s and static concentrations between drugs were minimized when data were expressed as multiples of the MIC, demonstrating the critical role of intrinsic drug activity (MIC) in eliciting the antibacterial intracellular effects, whereas accumulation per se was unimportant. CEM-101 should show enhanced in vivo potency if used at doses similar to those of the comparators tested here.
Macrolides have long been known for their large volume of distribution (3, 28) , which is related to their ability to accumulate inside eukaryotic cells by diffusion/segregation in acidic compartments, namely, lysosomes and related vacuoles (8, 9) . As a consequence, macrolides have been considered advantageous for the treatment of infections localized in these compartments (32, 48) . In a more general context, they are widely recommended for infections caused by typical intracellular pathogens such Legionella and Chlamydia, based on a large array of both in vitro (7, 17) and clinical (16, 19, 33, 38, 42) data. However, direct quantitative comparisons between intracellular and extracellular activities using facultative intracellular pathogens, such as Staphylococcus aureus or Listeria monocytogenes, suggest that macrolides express only a minimal fraction of their antibacterial potential intracellularly (5, 34, 36) , especially considering their great intracellular accumulation. This minimized antibacterial potential against organisms replicating in phagolysosomes and related vacuoles is most likely related to acidic pH, which is known to reduce the activity of macrolides. Another factor is that some organisms, such as L. monocytogenes, may actually replicate in other subcellular compartments. In addition, certain macrolides, such as azithromycin, are subject to active efflux from macrophages (35) , which further contributes to suboptimal intracellular activity (34) . Key progress in the discovery of new macrolides over the last 20 years has been heralded mainly by the observation that 11,12-carbamate analogs of clarithromycin carrying a lipophilic side chain show improved activity compared to the parent compound (15) . Together with the removal of the cladinose (1) , this led to the discovery and development of the ketolides, with telithromycin being the first candidate to receive clinical approval. The primary improvement generated by ketolides is activity against erythromycin-resistant organisms (45, 49) , but no true improvement in their activity in the intracellular environment has been achieved.
CEM-101 is a novel fluoroketolide containing an 11,12-carbamate-butyl- [1, 2, 3] -triazolyl-aminophenyl side chain (Fig. 1) . CEM-101 demonstrates enhanced potency compared to telithromycin, with activity against telithromycin-intermediate and telithromycin-resistant organisms. This enhanced activity of CEM-101 is probably due to a higher binding affinity to the ribosome (22) .
This enhanced activity prompted us to assess the cellular accumulation and intracellular activity of CEM-101 using models that have been developed for the study of the intracellular pharmacodynamics of antibiotics (4, 20) . Our data show that CEM-101 maintains the maximal efficacy of known macrolides and shows greater potency against intracellular forms of Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila than telithromycin, azithromycin, and clarithromycin. This improved potency of CEM-101 results from the combination of its higher intrinsic activity against S. aureus and possibly also L. pneumophila and the decreased detrimental effect of acidic pH on its activity.
MATERIALS AND METHODS
Cell lines. Experiments were performed with THP-1 cells (ATCC TIB-202; American Tissue Culture Collection, Manassas, VA), a human myelomonocytic cell line displaying macrophage-like activity, as described earlier (5) .
Assay of the cell-associated macrolides and calculation of the apparent cellular-to-extracellular-concentration ratios. Macrolides were assayed by a microbiological method, using S. aureus ATCC 25923 as a test organism and according to the general procedure described previously (35) . Cell proteins were measured in parallel using the Folin-Ciocalteu/biuret method (23) . The cell-associated contents in macrolides were expressed by reference to the total cell protein content and converted into apparent concentrations using a conversion factor of 5 l per mg of cell protein, an average value found for many cultured cells.
Bacterial strains, susceptibility testing, and 24-h dose-response curve studies with broth. S. aureus ATCC 25923 (methicillin [meticillin] sensitive), L. monocytogenes strain EGD, and L. pneumophila strain ATCC 33153 were used in the present study. MIC determinations were performed in Mueller-Hinton broth (for S. aureus) and tryptic soy broth (for L. monocytogenes) after a 24-h incubation, or in ␣-ketoglutarate-buffered yeast extract broth (for L. pneumophila) after a 48-h incubation. For S. aureus studies, 24-h concentration-response experiments in acellular medium were performed in Mueller-Hinton broth.
Cell infection and assessment of antibiotic intracellular activities. Infection of THP-1 cells and assessment of the intracellular activity of antibiotics were performed as described previously (5, 20) 
RESULTS
Cellular accumulation and modulation by acidic pH, monensin, and effux transporter inhibitors. In the first series of experiments, we examined the extent of CEM-101 accumulation in THP-1 macrophages and how this accumulation is influenced by (i) acidic pH, (ii) the addition of monensin, and (iii) efflux transporter inhibitors. As shown in Fig. 2A , the cellular uptake of CEM-101 proceeded almost linearly over time, reaching an accumulation level approximately 350-fold the extracellular concentration within 24 h. Figure 2B shows that the accumulation of both CEM-101 and azithromycin was drastically reduced when the experiments were conducted at acidic pH, with the change occurring almost entirely when the pH was brought from 7 to 6. Figure 2C shows that monensin, which is known to decrease the cellular accumulation of weak organic bases, also almost completely suppressed the accumulation of both CEM-101 and azithromycin. In contrast, verapamil, an inhibitor of the P-glycoprotein efflux transporter (P-gp, also known as MDR1), increased the accumulation of azithromycin without affecting that of CEM-101, whereas gemfibrozil, an inhibitor of multidrug resistance proteins (MRP) and other organic anion transporters did not affect either compound. tration was chosen to be relevant to the serum concentration of azithromycin (2) and CEM-101 (27, 39) , and the higher concentration was selected to be above the MIC of azithromycin for the organisms of interest. Results presented in Fig. 4 show that under these conditions, only CEM-101 was able to significantly decrease CFU in broth as well as in THP-1 macrophages at the 0.7-mg/liter concentration. At the 4-mg/liter concentration in broth, azithromycin eventually achieved the same antibacterial effect as CEM-101, but at a lower rate (5 h compared to 1 h). In THP-1 macrophages, no consistent activity was detected for azithromycin, even at the 4-mg/liter concentration, whereas CEM-101 again achieved a reduction of approximately 1.5 log 10 CFU, similar to the magnitude seen at the 0.7-mg/liter concentration. In all situations with CEM-101, the maximal decrease of CFU was obtained within 1 h and was maintained thereafter. We then performed concentration-response experiments at a fixed time point (24 h) Table 1 . The activities in both broth and THP-1 macrophages developed in a concentration-dependent fashion (following the law of mass action), as denoted by the sigmoidal shape of each best-fit function (Hill equation). In broth, the relative efficacy of CEM-101 (E max of Ϫ1.37 log 10 ) was similar to that of the other drugs (E max values of Ϫ1.00 to Ϫ1.41 log 10 ). In THP-1 macrophages, the relative efficacy of CEM-101 was significantly decreased compared to that in broth (E max of Ϫ0.86 log 10 ), but not to the same extent as those of the other drugs, which essentially became bacteriostatic only (E max values of 0.04 to Ϫ0.29 log 10 ). On a weight basis, CEM-101 had higher relative potencies (lower E 50 values) and lower static concentrations (lower C s values) than all three comparator drugs in both broth and in THP-1 macrophages. When the data were analyzed as a function of equipotent concentration (multiples of the MIC), these differences in EC 50 values were reduced, indicating that the MIC was the main driving parameter in this context. In broth, even when analyzed as multiples of the MIC, CEM-101 and clarithromycin still showed significantly lower EC 50 s than telithromycin and azithromycin. Of note, the relative potencies of all four drugs were systematically improved when tested in THP-1 macrophages compared to broth (lower EC 50 s, even when expressed in multiples of the MIC), indicating a corresponding 4-to 16-fold enhancement of apparent intrinsic activity. Modulation of the intracellular activity toward S. aureus by P-gp inhibitors. As verapamil increased the accumulation of azithromycin but not that of CEM-101, telithromycin, or clarithromycin, we examined whether it would also modulate the activities of these four drugs toward phagocytized S. aureus in a differential fashion. Concentration-effect experiments using the same protocol as that shown in Fig. 5 were therefore performed in the presence of verapamil (100 M). Verapamil did not modify the response to CEM-101, clarithromycin, or telithromycin; however, it significantly increased both the relative potency (decreased EC 50 ) and the relative efficacy (decreased E max ) of azithromycin. The increased relative potency and efficacy eventually made the azithromycin response indistinguishable from that of CEM-101 (see data in Fig. SP1 in the supplemental material). Gemfibrozil had no effect on any of the four antibiotics.
Activity against intraphagoctic L. monocytogenes and L. pneumophila. In the last series of experiments, we used the same approach as that used for S. aureus to assess the activities of CEM-101 and azithromycin against phagocytized L. monocytogenes and L. pneumophila to obtain information on concentration-effect relationships and on the corresponding pertinent pharmacological descriptors. As shown in Fig. 6 (see also Table 2 for numerical values), a relationship compatible with the Hill equation was observed in all cases, although the limited growth of L. pneumophila made the fitting of functions somewhat more uncertain. When the data were plotted against weight concentration, it clearly appeared that CEM-101 had a much higher relative potency (lower EC 50 ) than azithromycin FIG. 5. Concentration-effect relationships for CEM-101, telithromycin, clarithromycin, and azithromycin toward S. aureus (ATCC 25923) in broth (left panels) and after phagocytosis by THP-1 macrophages (right panels). The ordinate shows the change in CFU (⌬ log CFU) per ml (broth) or per mg of cell protein (THP-1 macrophages) at 24 h compared to the initial inoculum. The abscissa shows the concentrations of the antibiotics as follows: (i) top panels, weight concentrations (in mg/liter) in broth (left) or in the culture medium (right) and (ii) bottom panels, multiples of the MIC as determined in broth at pH 7.4. All values are means Ϯ standard deviations (SD) of three independent experiments (when not visible, SD bars are smaller than the symbols). Statistical analysis based on global analysis of curve-fitting parameters (one-way analysis of variance); the only significant difference is between CEM-101 and azithromycin in broth (P ϭ 0.04). Numerical values of the pertinent pharmacological descriptors and statistical analysis of their differences are shown in Table 1 
DISCUSSION
Lack of effective antimicrobial therapy results in intracellular survival of bacteria, which remains a major cause of bacterial spreading, life-threatening therapeutic failures, and establishment of chronic, relapsing infections. These situations are indeed clearly observed during the course of infections caused by the three organisms studied here, with typical examples being meningitis for L. monocytogenes (14, 18) ; invasion of lung macrophages for L. pneumophila (12, 41) ; and endocarditis (37), osteomyelitis (46) , and skin structure infections (25) for S. aureus.
While it has long been assumed that intracellular accumulation of an antibiotic is indicative of efficient activity against bacteria, pharmacodynamic evaluation of a large series of commonly used antibiotics has revealed that other parameters, such as intracellular bioavailability and modulation of activity in the infected compartment, are also critical (10, 44) . The present study confirms and significantly extends previous observations made with macrolides in this context (5, 11), thanks to the differential behaviors exhibited by CEM-101 compared to those by telithromycin, azithromycin, and clarithromycin.
The main findings in our study are that CEM-101 accumulates to a considerably larger extent than the comparators, including azithromycin, and consistently expresses greater potency (decreased values of EC 50 and C s ), while showing maximal efficacy (E max ) similar to those of the comparators tested here. This indicates that the improvements resulting from the structural modifications introduced in CEM-101 relate to modulation of pharmacokinetic properties and intrinsic activity (including its reduced susceptibility to physico-chemical conditions prevailing in the infected compartment) rather than to a change in its mode of action. Thus, by and large, CEM-101 exhibits the essentially bacteriostatic character of macrolides but expresses it better in the intracellular milieu and at considerably lower extracellular concentrations than the comparators.
The cellular accumulation of CEM-101 clearly results from the general mechanism of proton trapping of weak organic bases (13) envisaged for all macrolides (44) , as accumulation is almost completely suppressed, in parallel with that of azithromycin, by exposure to acid pH or to the proton ionophore monensin (43, 47) . Based on the general model of diffusion/ segregation of weak bases in acidic membrane-bound compartments (13), accumulation is determined by the number of ionizable groups and the ratios between the membrane permeability coefficients of the unionized and ionized forms of the drug. While CEM-101 has two ionizable functions, the pK a of the aminophenyltriazole is calculated to be less than 4, making the molecule largely monocationic (as clarithromycin and telithromycin) at neutral and even at lysosomal pH (ϳ5) (29) . In contrast, azithromycin has two ionizable functions, with pK a s of Ͼ6 (24), and is therefore dicationic intracellularly. CEM-101, however, possesses a fluoro substituent in position 2, which should make it more lipophilic than clarithromycin or telithromycin. Additional biophysical studies aiming at determining the ratio of the permeability constants of the unionized and ionized forms of CEM-101 in comparison with clarithromycin and telithromycin should be very informative in this context, as this parameter is as critical as the number of ionizable functions in determining the level of cellular accumulation of weak organic bases (13) . In another context, the greater cellular accumulation of CEM-101 is probably partially due to its insusceptibility to P-gp-mediated efflux (which is expressed by THP-1 macrophages under our culture conditions [21] ) in contrast to azithromycin. Potential improvement in the expression of CEM-101 activity in the intracellular milieu compared with that of azithromycin is strongly suggested by the experiments that examined the effect of acid pH on the MIC of CEM-101 against S. aureus. Intraphagocytic S. aureus survives and multiplies in the acidic environment of phagolysosomes of THP-1 cells (21, 36) , which may explain why CEM-101 systematically shows a higher relative potency (lower EC 50 and C s ) against this organism than azithromycin. The differential effect of acid pH on CEM-101 and azithromycin is probably also important to explain our observations with intraphagocytic L. pneumophila, as the differences between the two antibiotics cannot be fully explained either by differences in the MICs (as measured in broth by conventional techniques) or by the potentially greater accumulation of CEM-101. Interestingly, recent data suggest that active multiplication of the intracellular forms of L. pneumophila, contrary to what was originally thought, may require their transit and sojourn in an acidic vacuole with an average pH of 5.6 (40) . While the MICs of L. pneumophila could not be determined at this low value because of the lack of bacterial growth in vitro, the data obtained at pH 6.5 are suggestive of a reduced inhibitory effect of acidic pH on CEM-101 versus azithromycin. This behavior is not unique to CEM-101, as it is shared by telithromycin and clarithromycin (for which the MIC-pH relationships in broth are essentially parallel to that of CEM-101). This observation is in line with our suggestion that the aminophenyltriazole function does not become significantly ionized within the pH range of 5 to 7.4. What differentiates CEM-101 from these macrolides, however, is its considerably higher intrinsic activity (lower MIC). This allows for sufficient intracellular activity of CEM-101 at low pH, even when in cells at low intracellular concentrations, as evidenced from our data with intraphagocytic S. aureus.
In contrast to what was observed for S. aureus and L. pneumophila, CEM-101 does not express enhanced activity toward intraphagocytic L. monocytogenes beyond what can be attributed to its higher intrinsic activity (lower MIC). This is actually anticipated, since the MIC-pH relationships for the four macrolides against this organism in broth are essentially parallel, and L. monocytogenes is known to sojourn and multiply in the cytosol of many cell types (6, 31) , including THP-1 macrophages (30) , where pH is close to neutral and where the bulk of CEM-101 is not likely to accumulate.
In conclusion, the present study shows that the intracellular activity of macrolides can be differentiated based on the assessment of their relative potencies and, for organisms residing in compartments with an acid environment, their susceptibility to the negative effect of acid pH on their intrinsic activity. Conversely, and counter to the common belief but also observed in other situations (see reference 26 for a review), we show here that differences in total cell accumulation by themselves do not necessarily translate into commensurate differences in activities against the three organisms examined here. This raises important questions as to which fraction of cellassociated antibiotics is truly active.
The model used here suffers from several limitations related to the use of constant exposure of the infected cells to the drugs (a situation not common in vivo) and our inability to take protein binding into consideration (because of the low protein concentration in the cell culture medium [see the discussions in references 4 and 5]). Nevertheless, it may help in a judicious selection of drug candidates, based on the analysis of the parameters studied here. This may eventually lead to improved therapy for intracellular infections provided that (i) the modifications made to increase the intrinsic activity do not adversely alter the safety profile of the drugs, so that patients can be treated with doses creating extracellular concentrations similar to those of conventional macrolides, and (ii) accumulation and expression of activity in infected cells in vivo are correctly predicted from the present in vitro data. azithromycin: the only significant difference is between azithromycin without and with verapamil (P < 0.0001); similar conclusions are reached when performing statistical analyses of the differences between the pertinent pharmacological descriptors (E max , E 50 , C s ).
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